We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva Copaxone EU Label to Omit Pregnancy Contraindication
Read MoreHide Full Article
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) announced that it has received a positive outcome to remove the pregnancy contraindication from the label of its key drug Copaxone in the EU. The latest label update will improve the safety and tolerability profile of the multiple sclerosis drug.
The positive outcome was received through a variation report issued by the UK Medicines and Healthcare Products Regulatory Agency. However, the new label does recommend avoiding the drug during pregnancy unless its treatment benefits outweigh its risks.
On Monday, Teva announced the appointment of Dipankar Bhattacharjee to succeed Sigurdur (Siggi) Olafsson as President and Chief Executive Officer (CEO) of the global generic medicine group. Siggi is stepping down from the post of the CEO and he is due to retire at the end of the first quarter of 2017. Bhattacharjee, on the other hand, has been the CEO of Teva Generics Europe since 2013. Shares of Teva dropped more than 5% on Tuesday as Siggi’s departure took the investment community by surprise.
In fact, Teva’s share price has declined 46.6% so far this year, comparing unfavorably with the Zacks classified Generic Drugs industry’s 38.3% decline.
For Teva, 2016 has been a transitional year as it is working on the integration of Actavis Generics – Allergan plc’s generics business acquired in August – and is progressing with its branded pipeline. The Actavis Generics acquisition will help the company strengthen its position in the key generic markets. Teva is also looking to strengthen its biosimilar pipeline.
Meanwhile, Teva intends to accelerate growth platforms, protect and expand core franchises, expand its global presence, pursue strategic deals, and reduce the cost base. However, headwinds remain in the form of generic competition for Copaxone, as well as new competition for branded products. We note that Teva is facing patent challenges for the 40 mg formulation of Copaxone. Last June, Novartis AG’s (NVS - Free Report) generic arm, Sandoz, and partner Momenta Pharmaceuticals, Inc. launched Glatopa, the once-daily generic version of Copaxone 20 mg.
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Teva Copaxone EU Label to Omit Pregnancy Contraindication
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) announced that it has received a positive outcome to remove the pregnancy contraindication from the label of its key drug Copaxone in the EU. The latest label update will improve the safety and tolerability profile of the multiple sclerosis drug.
The positive outcome was received through a variation report issued by the UK Medicines and Healthcare Products Regulatory Agency. However, the new label does recommend avoiding the drug during pregnancy unless its treatment benefits outweigh its risks.
On Monday, Teva announced the appointment of Dipankar Bhattacharjee to succeed Sigurdur (Siggi) Olafsson as President and Chief Executive Officer (CEO) of the global generic medicine group. Siggi is stepping down from the post of the CEO and he is due to retire at the end of the first quarter of 2017. Bhattacharjee, on the other hand, has been the CEO of Teva Generics Europe since 2013. Shares of Teva dropped more than 5% on Tuesday as Siggi’s departure took the investment community by surprise.
In fact, Teva’s share price has declined 46.6% so far this year, comparing unfavorably with the Zacks classified Generic Drugs industry’s 38.3% decline.
For Teva, 2016 has been a transitional year as it is working on the integration of Actavis Generics – Allergan plc’s generics business acquired in August – and is progressing with its branded pipeline. The Actavis Generics acquisition will help the company strengthen its position in the key generic markets. Teva is also looking to strengthen its biosimilar pipeline.
Meanwhile, Teva intends to accelerate growth platforms, protect and expand core franchises, expand its global presence, pursue strategic deals, and reduce the cost base. However, headwinds remain in the form of generic competition for Copaxone, as well as new competition for branded products. We note that Teva is facing patent challenges for the 40 mg formulation of Copaxone. Last June, Novartis AG’s (NVS - Free Report) generic arm, Sandoz, and partner Momenta Pharmaceuticals, Inc. launched Glatopa, the once-daily generic version of Copaxone 20 mg.
Teva carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
TEVA PHARM ADR Price and Consensus
TEVA PHARM ADR Price and Consensus | TEVA PHARM ADR Quote
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>